Click for more information

6.98% 23.0¢

PHARMAUST LIMITED - Charts / Financials

PharmAust is a clinical-stage biotechnology company developing new therapeutics for human... PharmAust is a clinical-stage biotechnology company developing new therapeutics for human health. The Company's segments include Corporate and Research. The Company is focused on repurposing monepantel for the treatment of neurodegenerative diseases, in particular amyotrophic lateral sclerosis (ALS) - the most common form of motor neurone disease (MND). The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway which plays a central role in cell growth and proliferation and in degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease. The company successfully completed a Phase 1 study in monepantel as a treatment for ALS/MND with encouraging results. Monepantel has subsequently been accepted into the prestigious HEALEY ALS Platform Trial in the US. The company anticipates starting the Phase 2/3 study in H2 2024.More